Home › Paraganglioma › Tennessee
Paraganglioma clinical trials in Tennessee
3 studies for Paraganglioma are looking for participants at sites in Tennessee.
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Vanderbilt University Medical Center ( Site 0107), Nashville
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 25, 2026 · NCT04924075Familial Investigations of Childhood Cancer Predisposition
- St. Jude Children's Research Hospital, Memphis
RecruitingObservational study
All ages · All sexes · Updated Jun 17, 2026 · NCT03050268Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- Vanderbilt-Ingram Cancer Center, Nashville
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated May 14, 2026 · NCT05636618From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.